Article Text

PDF

Short communication
Actinobacillus pleuropneumoniae serovar 8 predominates in England and Wales
  1. Y. Li, BSc, PhD1,
  2. J. T. Bossé, BSc, MSc, PhD1,
  3. S. M. Williamson, BVetMed, PhD, MRCVS2,
  4. D. J. Maskell, BSc MA PhD FMedSci3,
  5. A. W. Tucker, BVetMed, PhD, MRCVS3,
  6. B. W. Wren, BSc PhD FRCPath4,
  7. A. N. Rycroft, BSc, PhD, FRSB, FRCPath5 and
  8. P. R. Langford, BSc, PhD, FRSB1
  9. BRADP1T Consortium
  1. 1Section of Paediatrics, Imperial College London, St Mary's Campus, London W2 1PG, UK
  2. 2APHA—Bury St Edmunds, Rougham Hill, Bury St Edmunds, Suffolk IP33 2RX, UK
  3. 3Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK
  4. 4Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK
  5. 5Department of Pathology and Pathogen Biology, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA, UK
  1. Correspondence to E-mail for correspondence: p.langford{at}imperial.ac.uk

Statistics from Altmetric.com

Actinobacillus pleuropneumoniae is a major cause of pleuropneumonia, an acute or chronic lung disease of pigs that causes significant morbidity, mortality and economic losses in the worldwide pig industry (Bossé and others 2002, Gottschalk 2012). There are 15 established serovars of the bacterium determined by the composition of the capsular polysaccharide (Gottschalk 2012) with another proposed based on serology alone (Sárközi and others 2015). Determining the serovar allows insights into the epidemiology of A. pleuropneumoniae, for example, to map outbreaks of disease, to identify introductions of serovars not previously detected in countries and to assist in the formulation of bacterin vaccines. Serovar prevalence varies from country to country and with time (Dubreuil and others 2000, Gottschalk 2015). For example, currently serovars 5 and 7 dominate in Canada (Gottschalk and Lacouture 2015), whereas until the 1990s, it was serovar 1 (Gottschalk 2015). In Australia, serovar 15 is highly prevalent (Turni and others 2014) but is rarely reported elsewhere, although it has been recently found in Canada (Gottschalk and Lacouture 2014) and possibly also in Japan (Koyama and others 2007).

The last prevalence study in the UK analysed A. pleuropneumoniae clinical isolates collected in England and Wales between the years 1995 and 2007, with serovar 8 predominant (O'Neill and others 2010). In that study, serovar was assigned on the basis of PCR amplification of chromosomal capsule-specific regions; immunological serotyping by slide agglutination having been shown erroneously to overestimate serovars 3 and 6 and underestimate serovar 8 prevalence. Similar underestimation and overestimation were also found in a study of Canadian isolates (Gottschalk 2015). In this study, the authors sought to determine whether the serotype prevalence of A. pleuropneumoniae in England and Wales had changed since 2007 and, in particular, whether new serovars, such as 15, were now present. The isolates evaluated were obtained from clinical cases of diseases in pigs due to A. pleuropneumoniae submitted to the Animal Health and Veterinary Laboratories Agency—Weybridge (AHVLA), now the Animal and Plant Health Agency (APHA), or Royal Veterinary College Diagnostic Laboratories. Isolates were collected between 2008 and 2014. For each year, the number of isolates (in brackets) is as follows: 2008 (N=14); 2009 (N=17); 2010 (N=8); 2011 (N=10); 2012 (N=30); 2013 (N=19) and 2014 (N=15). Bacteria were grown on plates comprising Brain Heart Infusion Agar supplemented with 10 µg/ml nicotinamide adenine dinucleotide. Initially, serotyping was assessed by a multiplex PCR that can distinguish between serovars 1–3, 5–8, 10 and 12 (Bossé and others 2014). The PCR was based on the authors’ original serovar 3–6–8 PCR (Zhou and others 2008) but extended to cover all of the serovars reported in England and Wales in the authors’ 2010 study (O'Neill and others 2010) and those reported to be prevalent in Europe and North America (Dubreuil and others 2000). A serovar 15-specific PCR (Turni and others 2014) was subsequently used on strains that were untypable by the 1–3, 5–8, 10 and 12 multiplex PCR. Genomic DNA purified using the QIAamp DNA Mini Kit (Qiagen) or single colonies were used as the source of DNA template for PCR reactions as previously described (Bossé and others 2014). In addition to serovar-specific amplicons, the multiplex PCR amplifies a region of the A. pleuropneumoniae-specific apxIVA gene (Schaller and others 2001, Bossé and others 2014). All isolates investigated in this study produced an apxIVA amplicon confirming that they were A. pleuropneumoniae. Comparison of the seroprevalence of A. pleuropneumoniae in England and Wales in this and the authors’ previous study is shown in Table 1.

TABLE 1:

Percentage serovar distribution of A. pleuropneumoniae isolates in England and Wales-based studies

As in the authors’ 2010 study, serovar 8 was the most predominant in years 2008–2014 in England and Wales, with a comparatively smaller percentage of serovars 2, 6, 7 and 12. The England and Wales serovar profile contrasts with that found in other European countries. For example, serovar 9/11 predominates in the Czech Republic (Kucerova and others 2005) and serovar 2 in Denmark (Klausen and others 2007), Norway and Sweden (Gottschalk 2012). No serovar 3 isolates were found, possibly reflecting the known low virulence of this serotype (Rosendal and others 1985), and that the A. pleuropneumoniae isolates evaluated were from clinically confirmed cases. Four isolates were non-typable (NT) and subsequent PCR testing established that these were not serovar 15 (Turni and others 2014). Due to their low numbers, the NT isolates were not tested further. The NT isolates could be serovars 4, 9/11, 13, 14, the newly described serovar 16 or variants such that the primers used did not anneal to genomic DNA. Among these, only serovar 9 has been previously reported in Great Britain (McDowell and Ball 1994) or Scotland (Anon 2013).

In summary, the authors’ results suggest that serovar 8 A. pleuropneumoniae remains the predominant serovar causing clinical disease outbreaks in England and Wales, as in the authors’ previous study. Any vaccine to be used in the UK to prevent disease caused by A. pleuropneumoniae should have a component targeting serovar 8 isolates and, for near-maximal coverage, additionally serovars 2, 6, 7 and 12.

Acknowledgments

This work was supported by a Longer and Larger (LoLa) grant from the Biotechnology and Biological Sciences Research Council (BBSRC grant numbers BB/G020744/1, BB/G019177/1, BB/G019274/1 and BB/G018553/1) and Zoetis (formerly Pfizer Animal Health) awarded to the Bacterial Respiratory Diseases of Pigs-1 Technology (BRaDP1T) Consortium. The BRaDP1T Consortium comprises Duncan J. Maskell, Alexander W. (Dan) Tucker, Sarah E. Peters, Lucy A. Weinert, Jinhong (Tracy) Wang, Shi-Lu Luan, Roy R. Chaudhuri (University of Cambridge; present address for R. Chaudhuri is Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, Western Bank, Sheffield S10 2TN, UK), Andrew N. Rycroft, Gareth A. Maglennon, Jessica Beddow (Royal Veterinary College); Brendan W. Wren, Jon Cuccui, Vanessa S. Terra (London School of Hygiene and Tropical Medicine) and Janine T. Bossé, Yanwen Li and Paul R. Langford (Imperial College London). The DEFRA-funded project “Scanning surveillance for Pig Diseases in England and Wales” (ED1200) funded laboratory and staff costs of obtaining the A. pleuropneumoniae isolates at APHA and the authors are grateful to veterinary and scientific staff at APHA Veterinary Investigation Centres.

  • Accepted June 19, 2016.

References

View Abstract

Footnotes

  • YL and JTB contributed equally.

  • Provenance: Not commissioned; internally peer reviewed

  • Competing interests None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.